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Abstract
Background: CDKN1C (also known as p57KIP2) is a cyclin-dependent kinase inhibitor previously
implicated in several types of human cancer. Its family members (CDKN1A/p21CIP1 and B/p27KIP1)
have been implicated in breast cancer, but information about CDKN1C's role is limited. We
hypothesized that decreased CDKN1C may be involved in human breast carcinogenesis in vivo.
Methods: We determined rates of allele imbalance or loss of heterozygosity (AI/LOH) in
CDKN1C, using an intronic polymorphism, and in the surrounding 11p15.5 region in 82 breast
cancers. We examined the CDKN1C mRNA level in 10 cancers using quantitative real-time PCR
(qPCR), and the CDKN1C protein level in 20 cancers using immunohistochemistry (IHC). All
samples were obtained using laser microdissection. Data were analyzed using standard statistical
tests.
Results: AI/LOH at 11p15.5 occurred in 28/73 (38%) informative cancers, but CDKN1C itself
underwent AI/LOH in only 3/16 (19%) cancers (p = ns). In contrast, CDKN1C mRNA levels were
reduced in 9/10 (90%) cancers (p < 0.0001), ranging from 2–60% of paired normal epithelium.
Similarly, CDKN1C protein staining was seen in 19/20 (95%) cases' normal epithelium but in only
7/14 (50%) cases' CIS (p < 0.004) and 5/18 (28%) cases' IC (p < 0.00003). The reduction appears
primarily due to loss of CDKN1C expression from myoepithelial layer cells, which stained intensely
in 17/20 (85%) normal lobules, but in 0/14 (0%) CIS (p < 0.00001). In contrast, luminal cells
displayed less intense, focal staining fairly consistently across histologies. Decreased CDKN1C was
not clearly associated with tumor grade, histology, ER, PR or HER2 status.
Conclusion: CDKN1C is expressed in normal epithelium of most breast cancer cases, mainly in
the myothepithelial layer. This expression decreases, at both the mRNA and protein level, in the
large majority of breast cancers, and does not appear to be mediated by AI/LOH at the gene. Thus,
CDKN1C may be a breast cancer tumor suppressor.
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Background
Cyclin-dependent kinases (CDK) are a family of enzymes
that govern the mammalian cell cycle (among other func-
tions) and whose aberrant upregulation can lead to onco-
genic effects. Consequently, proteins that negatively
regulate CDKs, cyclin-dependent kinase inhibitors
(CDKNs), are strong candidate tumor suppressor genes.
CDKNs fall into two families. The CDKN1 family contains
three members, called CDKN1A (also known as p21CIP)
[1], CDKN1B (also known as p27KIP1) [2,3] and CDKN1C
(also known as p57KIP2) [4,5]. CDKN1A and B play
important and complex roles in breast cancer, but knowl-
edge of CDKN1C's role is limited. The goal of this study is
to examine whether CDKN1C is implicated in human
breast cancers in vivo.
CDKN1C is a tight-binding inhibitor of several G1 cyclin/
CDK complexes and a negative regulator of the cell cycle
at the G1 checkpoint (for overview see [6]). The protein is
widely expressed and located in the nucleus. The gene lies
within an imprinted region, at chromosome 11p15.5-
p15.4, and undergoes incomplete paternal imprinting,
i.e., the maternal allele is expressed preferentially [7].
CDKN1C dysregulation – usually assessed as gene meth-
ylation or decreased mRNA expression – is seen in multi-
ple types of sporadic cancers (adrenal [8,9], head and neck
[10,11], gastrointestinal [12-15], urothelial [16,17] and
lung carcinomas [18-20]), as well as in gestational tro-
phoblastic disease [21], Wilms' tumor [22] and the Beck-
with-Wiedemann syndrome associated with organ
overgrowth [23]. Over-expression, or re-expression, of the
gene in vitro slows proliferation and shifts many cell types
into G1 [24-26].
Several in vitro observations support the hypothesis that
CDKN1C is implicated in breast tumorigenesis. First,
decreased CDKN1C expression occurs during human
mammary epithelial cell immortalization [27]. Second,
CDKN1C may be regulated by estradiol in mammary car-
cinoma cells [28]. Finally, CDKN1C may be regulated by
epigallocatechin-3-gallate (EGCG), a polyphenol in green
tea with anti-oxidant effects that may have cancer-sup-
pressive effects in general, and in breast cancer in particu-
lar [29-32].
CDKN1C's role in breast cancer in vivo has been consid-
ered previously, but data are limited. 11p15 undergoes
allele imbalance (AI) or loss of heterozygosity (LOH) in
35–40% of breast cancers [33-35], but CDKN1C does not
appear to be commonly mutated or rearranged [34,36].
The gene is hypermethylated in ~45% of primary tumors
[18]. Gene expression data available in repositories [37]
reveals that CDKN1C mRNA is present at relatively low
levels in both normal and cancerous breast tissue. We are
not aware of any reports examining CDKN1C protein
expression in human breast cancers.
Taken together, these data led us to investigate CDKN1C's
potential role as a tumor suppressor in breast cancer in
vivo. We speculated that the gene itself would not undergo
genomic alterations detectable by AI/LOH, but that
CDKN1C mRNA and protein levels would be diminished.
To ascertain whether the genetic alterations were present
in the epithelial compartment, as presumed, all tissues
examined were microdissected.
Methods
Tissue samples
After obtaining Boston University Medical Center institu-
tional review board approval, randomly-selected, de-iden-
tified, existing tissue samples not needed for diagnosis
were collected from 91 independent breast cancer cases
from Boston University Medical Center. In 87 cases, tis-
sues had been formalin-fixed and paraffin embedded
(FFPE). In 10 cases, tissues had been snap frozen, embed-
ded in optimal cutting temperature (OCT) medium and
stored at -80°C. One or more experienced breast patholo-
gist (AdlM, RP) reviewed all sections for accurate histo-
logic diagnoses.
Microdissection, DNA isolation and AI/LOH analysis
These procedures were carried out as described previously
[38-40]. FFPE or OCT embedded blocks were sectioned
and microdissected (PixCell, Arcturus Engineering,
Mountain View, CA) to isolate DNA from normal epithe-
lium, tumor and control tissue. PCRs were performed
using nine microsatellite probes: four at 11p15.4-.5
(D11s2071, D11s1318, THO1 and KIP2 – which is
located in a CDKN1C intron); 3 at 11q (PYGM (at
11q13.1) and D11s1818 and D11s1819 (at 11q23.1-.2),
and one each at 3p24.2-5 (D3s1283) and 7q31 (D7s486),
which served as control loci. Either a radioactive or fluo-
rescent [41] label was incorporated into the reactions. The
normal pattern at each microsatellite probe was defined as
its pattern in normal tissue of each individual (skin,
lymph node or normal breast epithelium). AI/LOH was
defined as an imbalance of 33% or more (allele ratio
>1.50 or <0.67). All abnormalities were demonstrated at
least twice with equivalent results.
Microdissection, RNA isolation and qPCR
Cases with available tissue were selected at random and
their OCT-embedded blocks were sectioned and micro-
dissected with the aid of pathologists to isolate normal
breast epithelium (terminal ducto-lobular units, or
TDLUs) and tumor [42]. Control RNA was extracted (Qia-
gen RNeasy Midi Kit, Qiagen, Valencia CA) from bulk nor-
mal-appearing tissue from a cancer-containing breast
stored in RNAlater (Qiagen). To prevent clogging of the
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RNeasy column by excess fat, the tissue homogenate was
spun at 6100 rpm for 10 minutes at 4°C and only the
aqueous layer was used for RNA purification. All RNA
samples were quantified spectrophotometrically (Nano-
drop Technologies, Wilmington, DE), and 1.0 ng RNA
from each sample was run on an RNA 6000 Pico LabChip
for the Agilent Bioanalyzer 2100 (Agilent Technologies,
Waldbronn, Germany) to confirm quality.
To produce cDNA, RT-PCR was performed on 5.0 ng of
each microdissected RNA sample using Taqman Gold RT-
PCR reagents (Applied Biosystems, Foster City, CA) in a
25 Pl reaction. Quantitative real-time PCR (qPCR) was
performed using Taqman Universal PCR Mastermix
(ABI), in independent 25 Pl reactions consisting of 11.25
Pl cDNA solution and an Assay on Demand (ABI) for
CDKN1C or glucuronidase B (GUSB), an endogenous
control gene located at 7q31 whose expression is similar
in normal and malignant breast tissue [43]. The CDKN1C
primers are designed to amplify the 3' end of the first and
the 5' end of the second exon. QPCR was performed using
an ABI Prism 7000 Sequence Detection System and ana-
lyzed using the SDS version 1.1 software (ABI). Standard
curves using the control RNA isolated from bulk normal
breast tissue were performed with every reaction. All reac-
tions were done twice, and an independent RT-PCR and
qPCR was performed for each replicate to reduce error and
allow greater accuracy when comparing reactions done at
different times.
Immunohistochemistry (IHC)
Cases with available FFPE blocks were selected at random
and 5 Pm sections were cut from FFPE blocks, mounted
on positively charged glass slides, dried at 60°C for 1 hr,
and deparaffinized. Endogenous peroxidase activity was
quenched with hydrogen peroxide/methanol for 15 mins.
Antigen retrieval was achieved by microwaving the slides
in a citrate buffer (Citrate Plus, Biogenex, San Ramon, CA)
on the high setting for 3–5 mins followed by the medium
setting for 8 mins. After washing, sections were incubated
for 1 hr at room temperature with a rabbit polyclonal anti-
CDKN1C antibody directed against the carboxy-terminus
of the protein (C-20, Santa Cruz, CA) at a 1:2000 dilution
of the stock solution. The negative control was a rabbit
polyclonal antibody pool (Biogenex). To localize sites of
primary antibody binding, sections were incubated with a
biotin-labeled goat anti-rabbit secondary antibody (20
mins) followed by streptavidin-HRP (20 mins) (LP000-
UL, Biogenex). After washing, sections were exposed to
the chromagen diaminobenzidine for 10 sec. before coun-
terstaining with hematoxylin for 30 sec.
Two pathologists [RP, AdlM] independently reviewed the
slides and recorded the proportion of cells with nuclear
staining in each type of lesion (normal epithelium, CIS,
IC). The proportion of cells with staining was assessed
separately for the myoepithelial and luminal regions. The
intensity of staining was graded using a semi-quantitative
0–3+ scale (0 = no staining, 1+ = weak, 2+ = moderate, 3+ =
strong). Placenta served as the positive control.
Statistical analyses
To compare rates of AI/LOH at separate probes, Fisher's
exact test was used. For the RNA expression data, Fried-
man's two-way non-parametric analysis of variance
(ANOVA) was used to compare two matched groups (nor-
mal and tumor) and each group was measured two times.
Within each sample, the values of the difference between
the Ct values ('Ct) of CDKN1C and GUSB were ranked.
Then the ranks were compared between the normal and
tumor groups to form a chi-square statistic with one
degree of freedom. For the IHC data, Fisher's exact test was
used to test the difference between two proportions (nor-
mal and CIS, normal and IC, or CIS and IC).
Results
Cases
Ninety-one breast cancers were analyzed. Of these, DNA
from 82 were analyzed for AI/LOH at four 11p15.5 and
five control loci, RNA from ten cases were analyzed for
expression of CDKN1C mRNA via qPCR, and tissues from
20 cases were analyzed for staining of CDKN1C protein
via IHC. The clinical-pathologic characteristics of the cases
used suggest that they represent an unselected group of
breast cancers. These characteristics are summarized in
Table 1.
DNA
82 breast cancer cases were analyzed for AI/LOH (nine
CIS, 73 IC). The results are summarized in Table 2. AI/
LOH at one or more markers on 11p15 was seen in 28/73
(38%) informative tumors, consistent with previous
reports [33,34,44-46]. In contrast, AI/LOH at CDKN1C
itself was seen in 3/16 (19%) informative tumors, a level
consistent with a background or non-specific rate. Results
were the same from frozen and FFPE samples. There were
no statistical differences between the rates of AI/LOH at
CDKN1C and any other 11p15 probe.
RNA
Cancer and paired normal epithelium from ten invasive
breast cancers were analyzed for CDKN1C RNA expres-
sion by qPCR. We found reduced expression of CDKN1C
in 9/10 (90%) cancers relative to its paired normal epithe-
lium, and normalized against GUSB (see Figure 1). The
'Ct between CDKN1C and GUSB for each normal sample
was compared to its paired tumor sample to generate the
relative expression of CDKN1C mRNA between tumor
and normal. This difference in relative expression of
mRNA between the cancer and normal groups was signif-
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icant (p < 0.0001). The fold changes in mRNA level were
moderate. As shown in Figure 1, CDKN1C mRNA levels in
nine cancers ranged from 2 – 60% of normal and in one
cancer was 282% of normal.
Protein
Twenty breast cancer cases were examined for CDKN1C
protein levels using IHC. Figure 2 shows representative
examples of staining. Overall, there was less CDKN1C
staining in both CIS and IC, compared to normal epithe-
lium. As shown in Figure 3a, staining of any intensity at
any location was present in 19/20 (95%) normal epithe-
lial samples, compared to 7/14 (50%) CIS (p = 0.004) and
5/18 (28%) IC (p = 0.00002). The difference between CIS
and IC was not significant.
CDKN1C protein expression did not appear to be distrib-
uted uniformly between the luminal and myoepithelial
layers. In normal lobules, the positively staining cells were
predominantly in the myoepithelial layer, as seen in Fig-
ure 2b. These cells stained intensely, usually 2+ – 3+. On
average, 46% of myoepithelial layer cells, from 17/20
(85%) cases, stained for CDKN1C. In contrast, no myoep-
ithelial layer cells (0%) stained for CDKN1C in any CIS
(0/14 (0%) cases). An example is shown in Figure 2c. By
definition, IC does not have a myoepithelial layer. In
luminal cells, CDKN1C staining was generally more focal,
less common, and less intense (1+ – 2+) than in myoepi-
thelial layer cells. In addition, luminal cell CDKN1C
staining was fairly similar across the three histologies. In
normal lobules, luminal cell staining was confined to 2%
of cells, from 4/20 (20%) cases, in CIS it was limited to
6% of cells, from 7/14 (50%) cases, and IC it was seen in
2% of cells from 5/18 (28%) cases. These results are
depicted in Figure 3b. Table 3 presents the IHC results for
each case.
Integration of DNA, RNA, and protein data
There were six cases with DNA, mRNA and protein data.
The findings in these cases were consistent with those of
the full group. None of the six had AI/LOH at CDKN1C,
but all had decreased mRNA levels. CDKN1C protein
staining was present in normal epithelium of 6/6 (100%)
cases (4 in the myoepithelial and 2 in luminal area cells),
and complete loss of staining was seen in 3/4 (75%) CIS
and 5/5 (100%) IC. These data are summarized in Table 4.
Clinical-pathological correlation
We tested for associations between AI/LOH at each DNA
marker,CDKN1C mRNA expression and protein staining,
and subject age, tumor histology, grade, ER/PR or HER2
status. The only association seen was between AI/LOH at
the THO1 marker and lack of ER/PR expression (p =
0.036). The other chromosome 11p markers, including
CDKN1C, were not significantly associated, nor was AI/
LOH at THO1 associated with other clinical-pathological
features.
Table 2: No increase in AL/LOH at CDKN1C in 82 primary breast 
cancers
Chromosomal locus and probes Number of cancers with AI/LOH (%)
11p15.4-.5 28/73 (38)
D11s2071 20/45 (44)
THO1 19/57 (33)
D11s1318 06/15 (40)
CDKN1C (KIP2) 03/16 (19)
11q13.1 09/32 (29)
PYGM 09/32 (29)
11q23.1-.2 34/71 (48)
D11s1818 24/55 (44)
D11s1819 23/47 (49)
3p24.2-5 09/27 (33)
D3s1283 09/27 (33)
7q31 08/39 (21)
D7s486 08/39 (21)
Table 1: Clinico-pathologic characteristics of study cases
DNA cases (%) RNA cases (%) Protein cases (%)
Total number of cases* 82 10 20
Age (years) 50 53 48
Age range (years) 33 to 92 33 to 92 30 to 62
Ductal carcinoma 76/81 (94) 10/10 (100) 20/20 (100)
Lobular carcinoma 6/81 (6) 0/10 (0) 0/20 (0)
Grade
1 of 3 5/71 (7) 0/10 (0) 1/20 (5)
2 of 3 18/71 (25) 3/10 (30) 6/20 (30)
3 of 3 48/71 (68) 7/10 (70) 13/20 (65)
ER and/or PR positive 45/65 (69) 7/10 (70) 15/20 (75)
Her2/neu positive 8/36 (22) 2/10 (20) 3/20 (15)
* In some cases complete clinico-pathologic data were not available
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Discussion
We speculated that CDKN1C might, like its family mem-
bers, be implicated in breast carcinogenesis in vivo. There-
fore, we investigated its DNA, mRNA and protein levels in
a series of primary breast cancers, compared to paired nor-
mal breast epithelium. Using microdissected samples, we
found that the gene does not appear to undergo AI/LOH,
but its mRNA level is reduced in 90% of cancers, and its
protein is completely absent in 50% of in situ and 72% of
invasive cancers. The reduction appears primarily due to
loss of CDKN1C expression from myoepithelial layer
cells, which stained intensely in 17/20 (85%) normal lob-
ules, but in 0/14 (0%) CIS (p < 0.00001). AI/LOH of the
11p15.4-5 region in general and decreased expression of
CDKN1C was not clearly associated with tumor grade,
histology, ER, PR or HER2 status. These data suggest
CDKN1C acts as a tumor suppressor in breast cancer, per-
haps in myoepithelial cells, and that its function may be
lost at or before the appearance of CIS. This study does not
investigate the mechanism of the gene's inactivation, but
our results are consistent with an epigenetic process, or
RNA interference, although other processes could be
involved as well.
These data raise several points for consideration. Gene
expression profiling data available at Gene Expression
Omnibus (last accessed 01-10-08 [37]) indicate that
CDKN1C mRNA expression is relatively low and not con-
sistently different between normal and cancerous breast
tissue. The data from primary tissues generally derive from
analysis of bulk normal and tumor samples that contain a
heterogeneous mix of cells. In contrast, we saw small but
widespread decreases in CDKN1C mRNA expression in
malignant epithelium, compared to normal. We may have
observed subtle but consistent decreases because we
microdissected our samples, which enriched them for epi-
thelium and unmasked the gene's potentially important
role. This speculation is supported by our finding that in
normal epithelium the expression appears localized
mainly in myoepithelium, which constitutes only a frac-
tion of the cells of the normal lobule. It is believed that a
functioning myoepithelium may suppress progression of
the neoplastic luminal cells [47]. Loss of myoepithelial
CDKN1C mRNA levels are decreased in primary breast cancersFigure 1
CDKN1C mRNA levels are decreased in primary breast cancers. Expression of CDKN1C mRNA in cancers and paired 
normal epithelium were measured by qPCR, and each was normalized against an endogenous control, GUSB. RNA levels are 
displayed on a logarithmic scale. Each bar represents the average results for each case. Bars are labeled with the case number 
and the percent level of expression of CDKN1C in the tumor compared to its own normal.
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CDKN1C protein expression could participate in the dys-
regulation of this process, resulting in cancer progression.
We note, however, that CDKN1C mRNA was not found to
be differentially expressed in one study comparing
myoepithelial with luminal cells [48]. This may reflect the
techniques used, or effects of post-transcriptional modifi-
cations leading to lack of concordance between mRNA
and protein. Furthermore, we cannot distinguish whether
the decreased CDKN1C mRNA expression we observe in
microdissected epithelium is due to all cells having mod-
erately decreased expression, or to a subpopulation [e.g.,
myoepithelial cells] having dramatically decreased expres-
sion, or to a decrease in the number of cells [e.g., myoep-
ithelial cells] with constant high expression. Future
experiments to address this question will be important.
Secondly, we see decreased mRNA in nearly all cases, but
the gene is reported to be methylated in only half that
number [18]. One potential explanation for this discrep-
ancy is that gene methylation may really be present in
nearly all cases, but has been hidden due to "contamina-
tion" by heterogeneous non-malignant cells with an
unmethylated gene. Another possibility is that alternative
mechanisms, such as histone modification, or post-tran-
scriptional effects, may lead to decreased RNA and, subse-
quently, protein, levels. Decreased CDKN1C mRNA
expression due to several mechanisms has recently been
described in primary pancreatic neoplasms [15].
Third, it is unknown how CDKN1C interacts with its fam-
ily members. The genes probably have some functional
Representative examples of CDKN1C immunohistochemistryFigure 2
Representative examples of CDKN1C immunohistochemistry. a) placenta, (positive control) with 3+ nuclear staining; 
b) normal breast epithelium, with 3+ nuclear staining located in the area of myoepithelium and no staining in the luminal epithe-
lium; c) DCIS, with no staining in the myoepithelium (see arrows) and 1–2+ focal nuclear staining in the malignant luminal epi-
thelium; d) IDC, with 1–2+ focal nuclear staining in malignant epithelium. 200×.
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redundancy, but there could be subsets of cells within
breast tissue with restricted expression of one or another
CDKN1 family member [49]. The CDKN1 family may
parallel the CDKN2 family, which also contains several
members with clear roles in carcinogenesis and one mem-
ber, (CDKN2B, or p15), whose role is unresolved.
There are several potential limitations to the present
study. First, our evaluation of DNA alterations is not com-
prehensive. We opted for this approach because previous
studies found sequence alterations to be uncommon, and
gene methylation to be present in nearly half of breast
cancers. Second, the number of cases examined is rela-
tively small. However, the results are remarkably uniform.
Third, we used a single set of primers and a single anti-
body to examine RNA and protein levels, respectively, and
thus may not have detected uncharacterized splice vari-
ants or aberrant proteins. CDKN1C contains 3 exons; the
second and third are coding and produce two isoforms by
alternative splicing. The long 316 amino acid (aa) isoform
is unprocessed, and the short, 305 aa isoform is missing
the first, or amino-terminal, 11 aa. Since we used an anti-
body directed at a carboxy-terminal epitope, both iso-
forms should have been detected. The RNA primers
spanned the first and second exon and should have
detected all transcripts. Fourth, we defined myoepithelial
cells by histologic appearance and location, not by addi-
tional stains. Finally, this study found a strong association
Table 3: CDKN1C protein expression by IHC in 20 breast cancer cases
Case 225 243 248 261 266 267 271 273 277 285 7018 7028 7030 7031 7036 7037 7040 7042 7043 7049
Myoepithelium (% of cells staining positive for CDKN1C)
TDLU 0 35 0 5 85 40 70 80 35 15 50 55 50 15 0 90 90 70 80 60
CIS 0 0 0 0 0 0 0 0 0 0 0 0 0 0
IC*
Luminal epithelium (% of cells staining positive for CDKN1C)
TDLU 20 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 5
CIS 25 0 0 0 10 0 5 0 0 10 15 0 5 10
IC 0 0 0 0 0 10 0 0 0 0 0 10 0 1 0 0 1 10
*By definition the invasive component does not have a myoepithelial layer. Blank box, not available for analysis
CDKN1C protein is decreased in breast cancerFigure 3
CDKN1C protein is decreased in breast cancer. a) The number of cases with positive staining for CDKN1C is plotted 
for each tissue type (normal epithelium, CIS and IC). b) The percent of cells staining for CDKN1C is plotted for myoepithelial 
and luminal area cells, in normal epithelium, CIS and IC. Each dot represents a separate case and the horizontal line indicates 
the median. IC by definition contain no myoepithelial cells.
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between CDKN1C and breast cancer, but cannot deter-
mine causality.
Conclusion
We find that the CDKN1C gene does not appear to
undergo frequent genetic alteration, as measured by AI/
LOH, but that mRNA and protein levels are decreased in
the large majority of breast cancers compared to paired
normal epithelium. The reduction in protein expression
appears mainly due to loss of expression in normal lob-
ule's myoepithelial layer cells. Combining these data with
existing knowledge of the gene's regulation and the pro-
tein's function, suggest that CDKN1C is a tumor suppres-
sor that could act early in breast carcinogenesis, perhaps
in the myoepithelial compartment.
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